#USA #Endo #Peyronie's Disease #XIAFLEX #Malvern, PA

Endo's Focus on Peyronie's Disease: AUA 2025 Presentation

Introduction
Endo, a subsidiary of Mallinckrodt plc, has announced its upcoming presentation focused on Peyronie's disease at the North Central Section of the American Urological Association (AUA) annual meeting, which will take place from October 15 to 18, 2025. This presentation showcases updated findings related to the use of XIAFLEX, a treatment that demonstrates promising efficacy and tolerability in managing this often-avoided condition.

Peyronie's Disease Overview
Peyronie's disease (PD) affects numerous men and is characterized by the formation of fibrous scar tissue, leading to curvature of the penis. It can cause discomfort and difficulties during sexual activity, making it a sensitive subject for many. It’s estimated that 1 in 10 men in the United States could experience PD; however, many do not seek help due to the stigma and embarrassment associated with the condition.

Presentation Highlights
Dr. Peter Bajic, an expert in urology and a representative from the Cleveland Clinic's Glickman Urological Institute, will present the key findings. The presentation titled, “Collagenase Clostridium Histolyticum (CCH) for Ventral Curvature (VC) of the Penis Due to Peyronie's Disease (PD)”, draws from a non-interventional, retrospective multicenter study that examined the application and effectiveness of CCH (the active ingredient in XIAFLEX).

The study evaluated adult men diagnosed with PD and ventral curvature, reviewing their medical charts for data on their treatment regimen and outcomes. The primary endpoint of the study was the percentage change in penile curvature, while secondary endpoints included the average change in curvature degree and the percentage of patients seeing a minimum of 30% improvement from their baseline to their last visit.

Notably, the findings reported no serious treatment-related adverse events, and instances of urethral injury were absent. The study’s outcomes reaffirm the notion that XIAFLEX is both effective and well tolerated among men with PD and VC, supporting its continued use as a nonsurgical intervention option for these individuals.

Impact on Treatment Options
These results are expected to encourage both clinicians and patients who are exploring nonsurgical treatment alternatives. The effectiveness of XIAFLEX—as evidenced by consistent results across various studies—is a significant milestone in managing Peyronie's disease. The research suggests that more educational efforts are necessary to encourage men to seek medical advice without fear or embarrassment.

Safety and Indications for XIAFLEX
XIAFLEX is specifically indicated for adult men experiencing Peyronie's disease with a palpable plaque and curvature of at least 30 degrees at the initiation of treatment. It is essential to note that the administration of this medication carries certain risks, including severe side effects such as penile fractures or allergic reactions. As such, patient education on possible symptoms of serious adverse reactions is crucial. Patients are advised to refrain from sexual activity during the treatment cycle to avoid complications.

Conclusion
Endo's presentation at the AUA 2025 highlights a commitment to advancing treatment options for Peyronie's disease, emphasizing the relevance of ongoing research and the importance of patient advocacy. As more findings emerge, it is hoped that greater awareness will be fostered, leading to improved patient outcomes and a better understanding of this challenging condition. Men experiencing symptoms related to PD are encouraged to consult their healthcare providers, as options like XIAFLEX could make a substantial difference in their quality of life.

For more information about this innovative treatment and the ongoing research being conducted, visit Endo’s website or connect through their professional networks. Together, we can work towards breaking the stigma around Peyronie's disease, fostering a dialogue that can change lives.